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Bactericidal activity of ﬂuoroquinolones
against plasmid-mediated QnrA-producing
Escherichia coli
The recent article in CMI by Rodriguez-Martinez
et al. [1] reported the effect of Qnr on the MICs of
nalidixic acid and ﬂuoroquinolones. The Qnr
determinant (recently named QnrA) has been
known to be plasmid-mediated since 1998 [2], and
is now reported increasingly worldwide [3].
QnrA binds to the subunits of DNA gyrase [4],
and confers, in terms of MICs, resistance to
nalidixic acid and decreased susceptibility to
ﬂuoroquinolones [1]. However, the effect of QnrA
on the bactericidal activity of ﬂuoroquinolones
has not been reported previously.
In order to investigate this effect, we performed
time-kill studies to analyse the bactericidal activity
of oﬂoxacin and ciproﬂoxacin, two ﬂuoroquinolo-
nes used extensively for treating Gram-negative
infections. The QnrA-positive strain used was
Escherichia coli J53 (pQR1), in which the QnrA
determinant was located on the 180-kb plasmid
pQR1, transferred by conjugation from clinical
isolate E. coli Lo, with E. coli J53 as control [3]. The
MICs of oﬂoxacin and ciproﬂoxacin for E. coli J53
(pQR1) were 1 mg ⁄L and 0.25 mg ⁄L, respectively
[3]. The materials and methods used were as
described previously [5]. Antibiotic concentrations
used in killing experiments were two-, four- and
eight-fold higher than the MICs. Viable counts
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Fig. 1. Bactericidal kinetics of oﬂoxacin (A) and ciproﬂoxacin (B) against Qnr-producing Escherichia coli J53 (pQR1), and of
oﬂoxacin (C) and ciproﬂoxacin (D) against E.coli J53. Symbols indicate inhibitory concentrations as follows: triangles,
2 · MIC; squares, 4 · MIC; open circles, 8 · MIC. Each point corresponds to the mean ± SD of three independent
determinations.
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were performed after 0, 2, 4 and 6 h. A bactericidal
effect was deﬁned as a ‡ 3 log10 (99.9% killing)
reduction in CFU compared with the initial test
inoculum. Colony counts were determined and
averaged from each sample.
The results are presented in Fig. 1. Oﬂoxacin
and ciproﬂoxacin showed bactericidal activity
against E. coli J53 (pQR1) at concentrations two-,
four- and eight-fold higher than the MICs, begin-
ning after incubation for 2 h and 4 h for oﬂoxacin
and ciproﬂoxacin, respectively. These results
indicated that transfer of QnrA into E. coli J53
did not modify the bactericidal activity of oﬂoxa-
cin and ciproﬂoxacin.
Martı´nez-Martı´nez et al. [2] reported that QnrA
mayenhance selectionof higher levels of quinolone
resistance [2]. The low level of resistance conferred
by QnrA may allow the bacterial population to
reach a concentration at which secondary chromo-
somal mutations for higher levels of quinolone
resistance may occur. However, the bactericidal
activity of ﬂuoroquinolones remained unchanged.
Our results indicate that, in the absence of addi-
tional chromosome-encoded quinolone resistance
mechanisms, QnrA-positive enterobacterial iso-
lates may remain susceptible to the bactericidal
effect of ﬂuoroquinolones. Animal infection mod-
els, as well as clinical studies, may provide further
evidence to support these in-vitro results.
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Correct use of the term ‘pan-drug-resistant’
(PDR) Gram-negative bacteria
We congratulate Hsueh et al. for their recent
publication in CMI regarding ‘pan-drug-resistant’
nosocomial Pseudomonas aeruginosa infections [1].
However, we would like to express our disagree-
ment with the use of the term ‘pan-drug-resistant’
(PDR) in this article. We believe that this term
should not be used for Gram-negative bacteria
that are susceptible to polymyxins. This practice
causes confusion among clinicians because it
suggests an absence of antimicrobial agents for
the management of infections caused by these
bacteria, while a potential salvage option is
available in the form of intravenous polymyxins.
An isolate of P. aeruginosa should be deﬁned as
‘pan-drug-resistant’ if it is resistant to all seven
available anti-pseudomonal classes of antimicro-
bial agents, namely anti-pseudomonal penicillins,
cephalosporins, carbapenems, monobactams,
quinolones, aminoglycosides and polymyxins
[2]. Several recent studies have used the term
‘pan-drug-resistant’ despite the fact that the iso-
lates had not been tested for their susceptibility to
polymyxins [3–5]. For example, a mortality rate of
60% was reported in a study of patients with
‘pan-drug-resistant’ Acinetobacter baumannii infec-
tions from Taiwan; however, the isolates were not
tested for their in-vitro susceptibility to polymyx-
ins. Furthermore, no polymyxin was used to treat
the patient population studied [3,4]. Several stud-
ies have now shown that intravenous polymyxins
may be useful for the treatment of patients with
infections caused by Gram-negative bacteria with
in-vitro susceptibility to these antibiotics, even if
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